What is HC Wainwright’s Forecast for Geron FY2028 Earnings?

Geron Co. (NASDAQ:GERN) – Stock analysts at HC Wainwright dropped their FY2028 earnings per share (EPS) estimates for Geron in a research report issued on Wednesday, May 7th. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will post earnings per share of $0.21 for the year, down from their prior estimate of $0.30. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Geron’s FY2029 earnings at $0.49 EPS.

Geron (NASDAQ:GERN) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The firm had revenue of $39.60 million for the quarter, compared to the consensus estimate of $49.88 million. During the same quarter in the previous year, the firm earned ($0.07) earnings per share. The firm’s revenue was up 12927.3% on a year-over-year basis.

A number of other analysts also recently commented on GERN. Barclays reiterated an “overweight” rating and set a $4.00 target price (down from $9.00) on shares of Geron in a research report on Thursday, February 27th. Needham & Company LLC reissued a “buy” rating and issued a $5.00 price objective on shares of Geron in a research note on Wednesday, March 12th. Stifel Nicolaus dropped their target price on shares of Geron from $8.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, February 27th. B. Riley downgraded shares of Geron from a “buy” rating to a “neutral” rating and reduced their price target for the company from $3.50 to $2.00 in a report on Thursday, February 27th. Finally, Scotiabank cut shares of Geron from a “sector outperform” rating to a “sector perform” rating and dropped their price objective for the stock from $4.00 to $1.50 in a research note on Thursday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $5.06.

Geron Price Performance

Shares of NASDAQ:GERN opened at $1.19 on Friday. The firm has a market capitalization of $754.74 million, a price-to-earnings ratio of -3.70 and a beta of 0.76. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The business’s 50 day simple moving average is $1.49 and its 200-day simple moving average is $2.73. Geron has a 12 month low of $1.17 and a 12 month high of $5.34.

Institutional Trading of Geron

Hedge funds have recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new position in shares of Geron during the 4th quarter worth $28,000. Integrated Wealth Concepts LLC purchased a new position in Geron during the fourth quarter worth about $36,000. Sowell Financial Services LLC purchased a new position in Geron during the first quarter worth about $43,000. GF Fund Management CO. LTD. acquired a new stake in Geron in the 4th quarter worth about $45,000. Finally, 111 Capital purchased a new stake in Geron in the 4th quarter valued at about $52,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.